SAN DIEGO--(BUSINESS WIRE)--Jun. 18, 2012--
Illumina (NASDAQ:ILMN) announced today that the company has filed an
additional patent infringement suit against Complete Genomics, Inc.
Illumina is seeking all available remedies, including injunctive relief.
The new suit, filed in the U.S. District Court for the Southern District
of California, is based on Complete Genomics’ infringement of U.S.
Patent No. 8,192,930, entitled “Method for Sequencing a Polynucleotide
Template.” The suit targets Complete Genomics’ Combinatorial
Probe-Anchor Ligation (cPal) read technology.
Illumina previously sued Complete Genomics for infringement of U.S.
Patent No. 6,306,597, in the U.S. District Court for the Northern
District of California. On February 8, 2012, the Court in that case
issued a Claim Construction Order providing the Court’s interpretation
of the disputed patent terms which affirmed the breadth of the patent
and supports Illumina’s position that Complete Genomics infringes that
Illumina is a leading developer, manufacturer, and marketer of life
science tools and integrated systems for the analysis of genetic
variation and function. Illumina owns or has exclusive licenses to more
than 250 patents granted in the U.S. and many additional patents granted
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Kevin Williams, MD